HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .
Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy
Objective : The aim of this study was to evaluate low-dose synthetic conjugated estrogens A ( SCE-A ) cream administered twice weekly for the treatment of moderate to severe vulvovaginal atrophy ( VVA ) in a symptomatic postmenopausal population . Methods : In a multicenter , double-blind , r and omized , placebo-controlled study , 305 women with symptoms of VVA were treated with either 1 g SCE-A cream ( n = 150 ) or matching placebo ( n = 155 ) for a period of up to 12 weeks . Participants had to have a vaginal pH of greater than 5 , less than or equal to 5 % superficial cells on a vaginal smear , and at least one of five symptoms of VVA ( dryness , soreness , irritation , pain with intercourse , and bleeding after intercourse ) that was moderate or severe in intensity . Women had to select one moderate or severe symptom as the most bothersome . Results : Efficacy was assessed at 2 , 3 , 4 , 8 , and 12 weeks and included the change from baseline in the severity of the most bothersome symptom ( MBS ) , maturation index , and pH. Most women identified vaginal dryness as the MBS ( 48 % ) followed by pain with intercourse ( 31.3 % ) . A statistically significant increase in the maturation index and significant decreases in pH and severity of the MBS were observed for those treated with SCE-A vaginal cream compared with placebo . Conclusions : A low dose ( 1 g = 0.625 mg ) of SCE-A vaginal cream administered twice weekly was shown to be effective compared with placebo in treating VVA in postmenopausal women for the three co primary efficacy measures of maturation index , pH , and severity of the MBS
HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .